Targeting the A2A receptor with a small molecule inhibitor, such as SCH58261, or with A2AR knockdown in cells using shRNA, triggers the enhancement of the cytotoxic function of anti-HER2 CAR-T cells either alone or in combination with anti-PD-1 therapy when transferred adoptively to tumor-bearing C57BL/6 mice (92). The gene discussed is ADORA2A; the disease is neoplasm.